Carcinoid syndrome describes multiple symptoms that develop from neuroendocrine tumors. While considered rare, these tumors can develop in the gastrointestinal tract or the lungs. Carcinoid ...

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Carcinoid syndrome is a rare condition typically affecting people with advanced carcinoid tumors. These rare, slow-growing tumors affect hormone-releasing neuroendocrine cells. The tumors can ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal ...

Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant ... glucagon) and tumor growth suppression in neuroendocrine tumors (NETs). As I noted before: In acromegaly, currently ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, ...

and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a ...

and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a ...

“The characteristics of NET vary widely from patient to patient, and very few treatment options have demonstrated the ability to improve outcomes across such a heterogeneous population,” said Jennifer ...